首页> 外文期刊>BMC Biotechnology >Evaluation of transduction efficiency in macrophage colony-stimulating factor differentiated human macrophages using HIV-1 based lentiviral vectors
【24h】

Evaluation of transduction efficiency in macrophage colony-stimulating factor differentiated human macrophages using HIV-1 based lentiviral vectors

机译:使用基于HIV-1的慢病毒载体评估巨噬细胞集落刺激因子分化的人类巨噬细胞的转导效率

获取原文
           

摘要

Background Monocyte -derived macrophages contribute to atherosclerotic plaque formation. Therefore, manipulating macrophage function could have significant therapeutic value. The objective of this study was to determine transduction efficiency of two HIV-based lentiviral vector configurations as delivery systems for the transduction of primary human blood monocyte-derived macrophages. Results Human blood monocytes were transduced using two VSV-G pseudotyped HIV-1 based lentiviral vectors containing EGFP expression driven by either native HIV-LTR (VRX494) or EF1α promoters (VRX1090). Lentiviral vectors were added to cultured macrophages at different times and multiplicities of infection (MOI). Transduction efficiency was assessed using fluorescence microscopy and flow cytometry. Macrophages transduced between 2 and 120 hours after culturing showed the highest transduction efficiency at 2-hours transduction time. Subsequently, cells were transduced 2 hours after culturing at various vector concentrations (MOIs of 5, 10, 25 and 50) to determine the amount of lentiviral vector particles required to maximally transduce human monocyte-derived macrophages. On day 7, all transduced cultures showed EGFP -positive cells by microscopy. Flow cytometric analysis showed with all MOIs a peak shift corresponding to the presence of EGFP -positive cells. For VRX494, transduction efficiency was maximal at an MOI of 25 to 50 and ranged between 58 and 67%. For VRX1090, transduction efficiency was maximal at an MOI of 10 and ranged between 80 and 90%. Thus, transductions performed with VRX1090 showed a higher number of EGFP -positive cells than VRX494. Conclusions This report shows that VSV-G pseudotyped HIV-based lentiviral vectors can efficiently transduce human blood monocyte-derived macrophages early during differentiation using low particle numbers that do not interfere with differentiation of monocytes into macrophages.
机译:背景单核细胞衍生的巨噬细胞有助于动脉粥样硬化斑块的形成。因此,操纵巨噬细胞功能可能具有重要的治疗价值。这项研究的目的是确定两种基于HIV的慢病毒载体构型作为转导原代人血单核细胞衍生巨噬细胞的传递系统的效率。结果使用两个基于VSV-G假型HIV-1的慢病毒载体转导人血单核细胞,这些载体包含由天然HIV-LTR(VRX494)或EF1α启动子(VRX1090)驱动的EGFP表达。将慢病毒载体在感染的不同时间和多重感染(MOI)时添加到培养的巨噬细胞中。使用荧光显微镜和流式细胞仪评估转导效率。培养2至120小时后转导的巨噬细胞在2小时转导时间显示最高的转导效率。随后,在各种载体浓度(5、10、25和50的MOI)下培养2小时后,转导细胞,以确定最大限度地转导人单核细胞衍生的巨噬细胞所需的慢病毒载体颗粒量。在第7天,所有转导的培养物通过显微镜检查均显示EGFP阳性细胞。流式细胞仪分析显示所有MOI的峰位移对应于EGFP阳性细胞的存在。对于VRX494,转导效率在MOI为25至50时最大,介于58%至67%之间。对于VRX1090,MOI为10时,转导效率最高,介于80%至90%之间。因此,与VRX494相比,用VRX1090进行的转导显示出更多的EGFP阳性细胞。结论该报告表明,基于VSV-G假型HIV的慢病毒载体可以在分化早期以低颗粒数有效地转导人血单核细胞衍生的巨噬细胞,而不会干扰单核细胞向巨噬细胞的分化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号